

Assessment, Public Health Activities, and the Studies Workgroups; and to address other issues and topics, as necessary.

*Matters To Be Discussed:* Agenda items include discussion on the summary of Hanford Health Information Network (HHIN) project, update on Individual Dose Assessment (IDA) project, and reports from agency and work groups. Agenda items are subject to change as priorities dictate.

*Contact Persons for More Information:* Leslie C. Campbell, Executive Secretary HHES, Division of Health Assessment and Consultation, ATSDR, 1600 Clifton Road, NE M/S E-56, Atlanta, Georgia 30333, telephone 1-888/42-ATSDR(28737), fax 404/639-0654.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 18, 2000.

**John Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 00-10081 Filed 4-23-00; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Health Statistics (NCHS), Data Policy and Standards Staff, Announces the Following Meeting

*Name:* ICD-9-CM Coordination and Maintenance Committee meeting.

*Time and Date:* 9 a.m.-5 p.m., May 11, 2000.

*Place:* The Health Care Financing Administration, Multipurpose room, 7500 Security Boulevard, Baltimore, Maryland.

*Status:* Open to the public.

*Purpose:* The ICD-9-CM Coordination and Maintenance (C&M) Committee will hold its first meeting of the calendar year 2000 cycle on Thursday, May 11, 2000. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Ninth-Revision, Clinical Modification.

*Matters to be Discussed:* Agenda items include:

Head injuries

Mammographic microcalcification

Myofascial pain syndrome

Stress Fracture

Periventricular leukomalacia

Posttraumatic wound infection versus complicated open wound

Premature menopause

Update on the ICD-10-PCS coding system

Thoracic aortic aneurysm repair

Lysis of adhesions

Penile plethysmography with nerve stimulation

Percutaneous endoscopic gastrojejunostomy (PEJ)

Spinal fusion for pseudoarthrosis

Addenda

*Contact Person for Additional Information:* Amy Blum, Medical Classification Specialist, Data Policy and Standards Staff, NCHS, 6526 Belcrest Road, Room 1100, Hyattsville, Maryland 20782, telephone 301/458-4106 (diagnosis), Amy Gruber, Health Insurance Specialist, Division of Acute Care, HCFA, 7500 Security Blvd., Room C4-07-07, Baltimore, Maryland, 21244 telephone 410-786-1542 (procedures).

*Notice:* In the interest of security, the H.C.F.A. has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

*Notice:* This is a public meeting. However, because of fire code requirements, should the number of attendants meet the capacity of the room the meeting will be closed.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 18, 2000.

**John Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 00-10082 Filed 4-23-00; 8:45 am]

**BILLING CODE 4160-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Invention; Availability for Licensing: "Prostate Cancer Therapeutic and *in vitro* Diagnostic Method to Screen for the Presence of Metastatic Prostate Cancer—A Monoclonal Antibody Specific to Prostate Cells"

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.

**ADDRESSES:** Licensing information may be obtained by contacting J. R. Dixon, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; E-Mail: jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required to receive a copy of any patent application.

#### SUPPLEMENTARY INFORMATION:

*Invention Title:* "Monoclonal Antibodies to Prostate Cells".

*Inventor:* Dr. Ira H. Pastan (NCI).  
USP SN: 5,489,525 [= DHHS Ref. No. E-201-92/0]—Issued on February 6, 1996.

#### Abstract

Prostate Cancer is a disease affecting approximately 1 million men in the U.S.A., with an annual incidence of around 179,000 and approximately 30,000 deaths per year. It is estimated that one-third of men over 50 will develop prostate cancer at some time in their lives. Control of primary tumor by surgical resection and/or radiation has proven effective in a number of cases, however, metastatic spread, primarily to the bone, especially at late hormone independent stages of the disease, has been more difficult to control and monitor. With the aging of the U.S. population, it has been estimated that the number of prostate cancer cases will increase dramatically.

#### Technology

The technology disclosed in the 5,489,525 patent relates to a monoclonal antibody which is capable of binding to a cell surface differentiation antigen